Orfiril (Sodium Valproate)

Sodium valproate, the active ingredient in Orfiril, is an anticonvulsant presented as an oral formulation for systemic use. It is employed to control generalized and focal seizures, stabilize mood in bipolar disorder, and prevent migraine attacks in adult patients.

GNH USA supplies Orfiril as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution. Customers benefit from reliable supply chains, competitive pricing, and responsive technical support.

Orfiril (sodium valproate) acts on neuronal excitability and is indicated for several neurological and psychiatric conditions.

Epilepsy (generalized and focal seizures): reduces seizure frequency and severity, improving daily functioning. Bipolar disorder (manic episodes): stabilizes mood and prevents manic relapses. Migraine prophylaxis: decreases the number of migraine attacks per month, helping to reduce disability.

Sodium valproate may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Nausea or gastrointestinal upset - Weight gain or increased appetite - Tremor or mild shakiness - Drowsiness or fatigue - Hair thinning or loss - Mild rash or skin irritation

Serious or Rare Side Effects: - Hepatotoxicity, including severe liver injury - Acute pancreatitis, presenting with abdominal pain - Severe skin reactions such as Stevens‑Johnson syndrome - Thrombocytopenia or significant drop in platelet count - Hyperammonemia leading to encephalopathy - Suicidal thoughts or mood changes

When prescribing Orfiril, clinicians should observe several safety considerations to minimize risk.

Pregnancy: Category D – use only if benefits outweigh potential fetal risks. Liver function: Monitor hepatic enzymes regularly, especially during the first six months. Blood counts: Periodic complete blood count to detect thrombocytopenia or leukopenia. Hypersensitivity: Discontinue if signs of allergic reaction such as rash or swelling occur. Metabolic disorders: Avoid in patients with known urea cycle defects or mitochondrial disorders. Store at ambient temperature: Keep below 25 °C in the original container, protect from moisture and direct sunlight.

Sodium valproate interacts with various medicines; some require avoidance while others need careful monitoring.

Major Interactions (Avoid): - Carbamazepine, phenytoin, phenobarbital: strong enzyme inducers that lower valproate levels. - Lamotrigine: concurrent use increases risk of severe skin reactions. - Other hepatotoxic drugs (e.g., isoniazid): may amplify liver injury risk.

Moderate Interactions (Monitor Closely): - Oral contraceptives: valproate can reduce contraceptive efficacy; additional methods advised. - Warfarin: valproate may enhance anticoagulant effect, requiring INR monitoring. - Acetaminophen (high doses): combined use can increase hepatic toxicity risk.